New Polymyalgia Rheumatica Treatment Approved in Europe
Adults with polymyalgia rheumatica can now access Cosentyx if they have an inadequate response to glucocorticoid treatment.
Updated on Oct. 21, 2026 in Arthritis
Live Poll
Do you believe new biologic treatments are improving long-term care for patients with chronic pain?
The European Commission has approved Cosentyx as a treatment for adults with polymyalgia rheumatica who have not responded adequately to glucocorticoids. This marks the first time an IL-17A inhibitor has been authorized for this inflammatory condition in Europe.
Why it matters
Polymyalgia rheumatica causes significant pain and stiffness in the neck, shoulders, and hips, yet advanced therapeutic options remain limited. This approval offers a new clinical pathway for managing relapses or treatment-resistant cases.
Data from the Phase III REPLENISH trial demonstrated that Cosentyx doubled sustained remission rates compared to placebo at Week 52 in patients with polymyalgia rheumatica. The study focused on individuals who had an inadequate response to or relapsed during glucocorticoid treatment.
The players
Novartis
A global pharmaceutical company that develops treatments for immunology, oncology, and cardiovascular diseases.
European Commission
The executive branch of the European Union responsible for healthcare policy and drug approvals across member states.
The details
Cosentyx functions as an IL-17A inhibitor, targeting specific inflammatory pathways associated with the condition. It is administered via subcutaneous injection and is intended to be used in conjunction with a tapering course of glucocorticoids. Clinicians may adjust the maintenance dosage from 150 mg to 300 mg based on a patient's individual clinical response.
Timeline
June 3-6, 2026: REPLENISH trial results presented at EULAR congress.
October 21, 2026: European Commission approves Cosentyx for polymyalgia rheumatica.
Health Landscape
The approval of Cosentyx represents a shift in the treatment of polymyalgia rheumatica, where options have historically relied heavily on glucocorticoids. This marks the first IL-17A inhibitor authorized for the condition, expanding the reach of targeted biologics beyond traditional standards of care.
For adults managing polymyalgia rheumatica, this development offers a potential new therapy for cases where glucocorticoids are insufficient. Patients struggling with persistent symptoms should consult their rheumatologist to discuss whether this treatment is an appropriate option for their specific needs.
The takeaway
While this approval provides a new tool for managing inflammatory symptoms in the neck, shoulders, and hips, decisions regarding biologics require careful coordination with your medical team. Always keep a detailed record of your symptoms and responses to existing medications to facilitate those conversations.
Further reading
Learn more about the latest research and treatment advancements in the Arthritis section.
Live Poll
Do you believe new biologic treatments are improving long-term care for patients with chronic pain?
